Clinically available GLP-1 receptor analogues, such as exenatide and liraglutide, are approved for treatment of type II diabetes since they reduce gastric emptying, glucagon secretion as well as enhance glucose-dependent insulin secretion [43-46]. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.